Stephen Gardner to Treatment Outcome
This is a "connection" page, showing publications Stephen Gardner has written about Treatment Outcome.
Connection Strength
0.111
-
A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects. Liver Int. 2014 Jul; 34(6):e89-95.
Score: 0.047
-
Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2005 Feb; 42(2):173-9.
Score: 0.026
-
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology. 2002 Jul; 36(1):186-94.
Score: 0.022
-
Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol. 2011 Dec; 55(6):1195-200.
Score: 0.010
-
Predictors of virologic response to Lamivudine treatment in children with chronic hepatitis B infection. Pediatr Infect Dis J. 2004 May; 23(5):441-5.
Score: 0.006